TSPO Imaging in Glioblastoma Multiforme: A Direct Comparison Between 123I-CLINDE SPECT, 18F-FET PET, and Gadolinium-Enhanced MR Imaging
Research output: Contribution to journal › Comment/debate › Research › peer-review
Standard
TSPO Imaging in Glioblastoma Multiforme : A Direct Comparison Between 123I-CLINDE SPECT, 18F-FET PET, and Gadolinium-Enhanced MR Imaging. / Jensen, Per; Feng, Ling; Law, Ian; Svarer, Claus; Knudsen, Gitte M; Mikkelsen, Jens D; de Nijs, Robin; Larsen, Vibeke A; Dyssegaard, Agnete; Thomsen, Gerda; Fischer, Walter; Guilloteau, Denis; Pinborg, Lars H.
In: Journal of Nuclear Medicine, Vol. 56, No. 9, 09.2015, p. 1386-90.Research output: Contribution to journal › Comment/debate › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - TSPO Imaging in Glioblastoma Multiforme
T2 - A Direct Comparison Between 123I-CLINDE SPECT, 18F-FET PET, and Gadolinium-Enhanced MR Imaging
AU - Jensen, Per
AU - Feng, Ling
AU - Law, Ian
AU - Svarer, Claus
AU - Knudsen, Gitte M
AU - Mikkelsen, Jens D
AU - de Nijs, Robin
AU - Larsen, Vibeke A
AU - Dyssegaard, Agnete
AU - Thomsen, Gerda
AU - Fischer, Walter
AU - Guilloteau, Denis
AU - Pinborg, Lars H
N1 - © 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
PY - 2015/9
Y1 - 2015/9
N2 - UNLABELLED: Here we compare translocator protein (TSPO) imaging using 6-chloro-2-(4'-(123)I-iodophenyl)-3-(N,N-diethyl)-imidazo[1,2-a]pyridine-3-acetamide SPECT ((123)I-CLINDE) and amino acid transport imaging using O-(2-(18)F-fluoroethyl)-l-tyrosine PET ((18)F-FET) and investigate whether (123)I-CLINDE is superior to (18)F-FET in predicting progression of glioblastoma multiforme (GBM) at follow-up.METHODS: Three patients with World Health Organization grade IV GBM were scanned with (123)I-CLINDE SPECT, (18)F-FET PET, and gadolinium-enhanced MR imaging. Molecular imaging data were compared with follow-up gadolinium-enhanced MR images or contrast-enhanced CT scans.RESULTS: The percentage overlap between volumes of interest (VOIs) of increased (18)F-FET uptake and (123)I-CLINDE binding was variable (12%-42%). The percentage overlap of MR imaging baseline VOIs was greater for (18)F-FET (79%-93%) than (123)I-CLINDE (15%-30%). In contrast, VOIs of increased contrast enhancement at follow-up compared with baseline overlapped to a greater extent with baseline (123)I-CLINDE VOIs than (18)F-FET VOIs (21% vs. 8% and 72% vs. 55%).CONCLUSION: Our preliminary results suggest that TSPO brain imaging in GBM may be a useful tool for predicting tumor progression at follow-up and may be less susceptible to changes in blood-brain barrier permeability than (18)F-FET. Larger studies are warranted to test the clinical potential of TSPO imaging in GBM, including presurgical planning and radiotherapy.
AB - UNLABELLED: Here we compare translocator protein (TSPO) imaging using 6-chloro-2-(4'-(123)I-iodophenyl)-3-(N,N-diethyl)-imidazo[1,2-a]pyridine-3-acetamide SPECT ((123)I-CLINDE) and amino acid transport imaging using O-(2-(18)F-fluoroethyl)-l-tyrosine PET ((18)F-FET) and investigate whether (123)I-CLINDE is superior to (18)F-FET in predicting progression of glioblastoma multiforme (GBM) at follow-up.METHODS: Three patients with World Health Organization grade IV GBM were scanned with (123)I-CLINDE SPECT, (18)F-FET PET, and gadolinium-enhanced MR imaging. Molecular imaging data were compared with follow-up gadolinium-enhanced MR images or contrast-enhanced CT scans.RESULTS: The percentage overlap between volumes of interest (VOIs) of increased (18)F-FET uptake and (123)I-CLINDE binding was variable (12%-42%). The percentage overlap of MR imaging baseline VOIs was greater for (18)F-FET (79%-93%) than (123)I-CLINDE (15%-30%). In contrast, VOIs of increased contrast enhancement at follow-up compared with baseline overlapped to a greater extent with baseline (123)I-CLINDE VOIs than (18)F-FET VOIs (21% vs. 8% and 72% vs. 55%).CONCLUSION: Our preliminary results suggest that TSPO brain imaging in GBM may be a useful tool for predicting tumor progression at follow-up and may be less susceptible to changes in blood-brain barrier permeability than (18)F-FET. Larger studies are warranted to test the clinical potential of TSPO imaging in GBM, including presurgical planning and radiotherapy.
KW - Aged
KW - Bicyclo Compounds, Heterocyclic
KW - Biomarkers, Tumor
KW - Brain Neoplasms
KW - Female
KW - Fluorodeoxyglucose F18
KW - Gadolinium
KW - Glioblastoma
KW - Humans
KW - Image Interpretation, Computer-Assisted
KW - Magnetic Resonance Imaging
KW - Male
KW - Middle Aged
KW - Molecular Imaging
KW - Radiopharmaceuticals
KW - Receptors, GABA
KW - Reproducibility of Results
KW - Sensitivity and Specificity
KW - Tissue Distribution
KW - Tomography, Emission-Computed
KW - Tyrosine
U2 - 10.2967/jnumed.115.158998
DO - 10.2967/jnumed.115.158998
M3 - Comment/debate
C2 - 26182972
VL - 56
SP - 1386
EP - 1390
JO - The Journal of Nuclear Medicine
JF - The Journal of Nuclear Medicine
SN - 0161-5505
IS - 9
ER -
ID: 162647472